REFRACTORY AL AMYLOIDOSIS
Clinical trials for REFRACTORY AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for REFRACTORY AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat amyloidosis
Disease control Recruiting nowThis early-phase study is testing the safety and best dose of a three-drug combination (venetoclax, ixazomib, and dexamethasone) for adults with light chain amyloidosis that has returned or stopped responding to prior treatments. The study is specifically for patients who have a …
Matched conditions: REFRACTORY AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Dual-Attack cell therapy trial offers hope for Tough-to-Treat amyloidosis
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy called AZD0120 in people with AL amyloidosis that has come back or hasn't responded to prior treatments. The therapy involves modifying a patient's own immune cells to target and destroy the harmful cells causing the d…
Matched conditions: REFRACTORY AL AMYLOIDOSIS
Phase: PHASE1, PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 04, 2026 15:30 UTC